Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally
✍ Scribed by Yuri Ghendon; Stanislav Markushin; Yuri Vasiliev; Irina Akopova; Irina Koptiaeva; Georgy Krivtsov; Olga Borisova; Nelly Ahmatova; Ekaterina Kurbatova; Svetlana Mazurina; Valentina Gervazieva
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 212 KB
- Volume
- 81
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Studies on mice showed that chitosan as an adjuvant for H5 inactivated influenza vaccines administered intramuscularly enhances significantly antibody titers and protective efficiency not only against homologous influenza viruses, but also against drift variants. Chitosan adjuvanted vaccines induced high antibody titers after a single immunization and with a low dose of antigen. High antibody titers remained for at least 6 months. Chitosan adjuvanted vaccine stored at 4°C preserves its adjuvant properties for at least 8 months. Chitosan stimulates proliferative and cytotoxic activity of splenic mononuclear leukocytes in mice and promotes an increase in the numbers of CD3, CD3/NK, I‐AK (MHC II), and H‐2Db (MHC I) cells. After intramuscular immunization, chitosan did not induce IgE antibodies and antibodies against chitosan itself. Chitosan is a promising adjuvant candidate for inactivated influenza vaccines administered parenterally. J. Med. Virol. 81:494–506, 2009. © 2009 Wiley‐Liss, Inc.